Expand all sections

Tislelizumab

Tevimbra

Extended indication Locally advanced or metastatic (Stage IIIB or IV), NSCLC (squamous or non-squamous) who have disease
Therapeutic value Possibly no place in the treatment regimen
Registration phase Registration application pending

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information